KNSA

Kiniksa Pharmaceuticals International Stock Analysis

AI Rating

Great
  • Quality9/10
  • Growth↑ 9/10
  • Momentum↑ 8/10
Kiniksa Pharmaceuticals International sales and earnings growth
KNSA Growth
Great
  • Revenue Y/Y↑ 55.68%
  • EPS Y/Y↑ 476.92%
  • FCF Y/Y↑ 814.13%
Kiniksa Pharmaceuticals International gross and profit margin trends
KNSA Profitability
Great
  • Gross margin ↑ 87.50%
  • EPS margin↓ 6.00%
  • ROIC↓ 14.10%
Kiniksa Pharmaceuticals International net debt vs free cash flow
KNSA Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Kiniksa Pharmaceuticals International stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗